Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 –  – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 –  – CIMERLI® net...

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium – Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel...

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress – Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support...

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) – Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –...

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology...